Literature DB >> 12704805

Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c.

Shigeki Ohmachi1, Tadahisa Mikami, Morichika Konishi, Ayumi Miyake, Nobuyuki Itoh.   

Abstract

Degeneration of dopaminergic neurons of the substantia nigra causes Parkinson's disease. Therefore, neurotrophic factors for dopaminergic neurons are of substantial clinical interest. Fibroblast growth factor (FGF)-20 preferentially expressed in the substantia nigra pars compacta (SNPC) of the rat brain significantly enhanced the survival of midbrain dopaminergic neurons. Here we examined the mechanism of action of FGF-20 on dopaminergic neurons. FGF-20 slightly enhanced the survival of total neurons of the midbrain, indicating that it preferentially enhanced the survival of dopaminergic neurons. FGF receptor (FGFR)-1c was found to be expressed abundantly in dopaminergic neurons in the SNPC but at much lower levels in neurons of other midbrain regions by in situ hybridization. FGF-20 was also found to bind FGFR-1c with high affinity with the BIAcore system. Furthermore, FGF-20 activated the mitogen-activated protein kinase (MAPK) pathway, which is the major intracellular signaling pathway of FGFs. Both the FGFR-1 inhibitor SU5402 and the MAPK pathway inhibitor PD98059 also significantly inhibited the activation of the MAPK pathway by FGF-20 and the neurotrophic activity of FGF-20. The present findings indicate that the activation of the MAPK pathway by FGF-20 signaling through FGFR-1c plays important roles in the survival of dopaminergic neurons in the SNPC. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704805     DOI: 10.1002/jnr.10592

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  32 in total

1.  Genetic variation in FGF20 modulates hippocampal biology.

Authors:  Herve Lemaitre; Venkata S Mattay; Fabio Sambataro; Beth Verchinski; Richard E Straub; Joseph H Callicott; Raja Kittappa; Thomas M Hyde; Barbara K Lipska; Joel E Kleinman; Ronald McKay; Daniel R Weinberger
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

Review 2.  Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease.

Authors:  Nobuyuki Itoh; David M Ornitz
Journal:  J Biochem       Date:  2010-10-12       Impact factor: 3.387

Review 3.  MicroRNAs in neurodegenerative diseases and their therapeutic potential.

Authors:  Eunsung Junn; M Maral Mouradian
Journal:  Pharmacol Ther       Date:  2011-10-08       Impact factor: 12.310

4.  Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix.

Authors:  Juliya Kalinina; Sara A Byron; Helen P Makarenkova; Shaun K Olsen; Anna V Eliseenkova; William J Larochelle; Mohanraj Dhanabal; Steven Blais; David M Ornitz; Loren A Day; Thomas A Neubert; Pamela M Pollock; Moosa Mohammadi
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

5.  ES cell-derived renewable and functional midbrain dopaminergic progenitors.

Authors:  Sangmi Chung; Jung-Il Moon; Amanda Leung; Daniel Aldrich; Stefan Lukianov; Yui Kitayama; Sara Park; Yan Li; Vadim Y Bolshakov; Thomas Lamonerie; Kwang-Soo Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

6.  FGF/EGF signaling regulates the renewal of early nephron progenitors during embryonic development.

Authors:  Aaron C Brown; Derek Adams; Mark de Caestecker; Xuehui Yang; Robert Friesel; Leif Oxburgh
Journal:  Development       Date:  2011-10-26       Impact factor: 6.868

Review 7.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

8.  Quantitative assessment of the association between fibroblast growth factor 20 rs1721100 C/G polymorphism and the risk of sporadic Parkinson's diseases: a meta-analysis.

Authors:  Ze-Gang Ma; Jian Xu; Tian-Wei Liu
Journal:  Neurol Sci       Date:  2014-07-17       Impact factor: 3.307

9.  Association between FGF20 rs12720208 gene polymorphism and Parkinson's disease: a meta-analysis.

Authors:  Xianjing Zhao; Yanfeng Wu; Can Zhao; Meijiang Feng
Journal:  Neurol Sci       Date:  2016-03-29       Impact factor: 3.307

10.  Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease.

Authors:  Joelle M van der Walt; Maher A Noureddine; Raja Kittappa; Michael A Hauser; William K Scott; Ron McKay; Fengyu Zhang; Jeffrey M Stajich; Kenichiro Fujiwara; Burton L Scott; Margaret A Pericak-Vance; Jeffery M Vance; Eden R Martin
Journal:  Am J Hum Genet       Date:  2004-04-30       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.